RZLT Company Profile and Key Details
Rezolute, Inc.
RZLT Stock Price Chart
Stock Price Today
Rezolute, Inc. (RZLT) stock declined over -2.24%, trading at $4.81 on NASDAQ, down from the previous close of $4.92. The stock opened at $4.93, fluctuating between $4.79 and $5.07 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Company Information
| Employees | 59 |
| Beta | 1.19 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Rezolute, Inc. (NASDAQ: RZLT) stock price is $4.81 in the last trading session. During the trading session, RZLT stock reached the peak price of $5.07 while $4.79 was the lowest point it dropped to. The percentage change in RZLT stock occurred in the recent session was -2.24% while the dollar amount for the price change in RZLT stock was -$0.11.
The NASDAQ listed RZLT is part of Biotechnology industry that operates in the broader Healthcare sector. Rezolute, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Robyn Sweinhart
Vice President & Head of Quality
Dr. Brian Kenneth Roberts M.D.
Chief Medical Officer
Dr. Davelyn Eaves Hood M.B.A., M.D.
Director and Head of Scientific & Patient Affairs
Dr. Raj Agrawal M.D.
Vice President & Head of Ophthalmological Clinical Devel.
Mr. Chris Milks
Vice President & Head of Fin.
Mr. Nevan Charles Elam J.D.
Founder, Chief Executive Officer & Acting Chairman
Mr. Michael Covarrubias
Senior Vice President & Head of Program & Portfolio Management
Ms. Erin O'Boyle
Senior Vice President & Head of Clinical Operations
Mr. Michael R. Deperro
Senior Vice President & Head of Corporation Devel.
RZLT's closing price is 422.83% higher than its 52-week low of $0.92 where as its distance from 52-week high of $6.19 is -22.24%.
Number of RZLT employees currently stands at 59.
Official Website of RZLT is: https://www.rezolutebio.com
RZLT could be contacted at phone 650 206 4507 and can also be accessed through its website. RZLT operates from 201 Redwood Shores Parkway, Redwood City, CA 94065, United States.
RZLT stock volume for the day was 399.06K shares. The average number of RZLT shares traded daily for last 3 months was 380.86K.
The market value of RZLT currently stands at $278.71M with its latest stock price at $4.81 and 57.94M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com